The Progression of Pre-invasive to Invasive Cancer

Chapter

Abstract

Most human invasive carcinomas are thought to evolve through a series of increasingly abnormal “stages” over many years, decades in most cases. In general terms, the stages are often referred to as hyperplasia, atypical hyperplasia, and carcinoma in situ. The transition from one stage to the next is primarily dependent on the accumulation of random genetic mutations in epithelial cells, so progression is non-obligatory. It is becoming clear that other forces are also at play, such as alterations of epigenetic gene regulation, and adjacent stromal cells promoting tumor progression, among others, which we are only beginning to understand. Carcinoma in situ is a late stage of tumor progression, and the immediate precursor of invasive disease. In this setting, “carcinoma” means that there is an ab­normal increase in the growth of tumor epithelial cells which accumulate in their normal environment (e.g. within ducts and lobules of the breast), but they do not invade out into the surrounding stroma or beyond. This chapter will discuss the development of invasive breast carcinomas (IBCs) as an example of the evolution of malignant epithelial neoplasms in general (Fig. 5.1). The general principles of the development and progression of invasive carcinomas are similar in many solid organs, although specific details may vary.

Keywords

Estrogen Stratification Luminal 

References

  1. 1.
    Allred DC, Hilsenbeck SG, Mohsin SK (2004) Biologic features of human premalignant breast disease. In: Harris JR, Lippman ME, Morrow M et al (eds) Diseases of the breast. Lippincott Williams & Wilkins, Philadelphia, pp 512–513Google Scholar
  2. 2.
    Wellings RR, Jensen HM (1973) On the origin and progression of ductal carcinoma in the human breast. J Natl Cancer Inst 50:1111–1118PubMedGoogle Scholar
  3. 3.
    Wellings SR, Jensen HM, Marcum RG (1975) An atlas of subgross pathology of the human breast with special reference to possible precancerous lesions. J Natl Cancer Inst 55:231–273PubMedGoogle Scholar
  4. 4.
    Deng G, Lu Y, Zlotnikov G et al (1996) Loss of heterozygosity in normal tissue adjacent to breast carcinomas. Science 274:2057–2059PubMedGoogle Scholar
  5. 5.
    Larson PS, de las Morenas A, Bennett SR et al (2002) Loss of heterozygosity or allele imbalance in histologically normal breast epithelium is distinct from loss of heterozygosity or allele imbalance in co-existing carcinomas. Am J Pathol 161:283–290PubMedGoogle Scholar
  6. 6.
    Bean GR, Bryson AD, Pilie PG et al (2007) Morphologically normal-appearing mammary epithelial cells obtained from high-risk women exhibit methylation silencing of INK4a/ARF. Clin Cancer Res 13:6834–6841PubMedGoogle Scholar
  7. 7.
    Crawford YG, Gauthier ML, Joubel A et al (2004) Histologically normal human mammary epithelia with silenced p16(INK4a) overexpress COX-2, promoting a premalignant program. Cancer Cell 5:263–273PubMedGoogle Scholar
  8. 8.
    Holst CR, Nuovo GJ, Esteller M et al (2003) Methylation of p16(INK4a) promoters occurs in vivo in histologically normal human mammary epithelia. Cancer Res 63:1596–1601PubMedGoogle Scholar
  9. 9.
    Lee S, Mohsin SK, Mao S, et al. Hormones, receptors, and growth in hyperplastic enlarged lobular units: early potential precursors of breast cancer. Breast Cancer Res 2005;8:http://breast-cancer-research.com/content/8/1/R6
  10. 10.
    Shaaban AM, Sloane JP, West CR et al (2002) Breast cancer risk in usual ductal hyperplasia is defined by estrogen receptor-alpha and Ki-67 expression. Am J Pathol 160:597–604PubMedGoogle Scholar
  11. 11.
    Martin AM, Weber BL (2000) Genetic and hormonal risk factors in breast cancer. J Natl Cancer Inst 92:1126–1135PubMedGoogle Scholar
  12. 12.
    Frech MS, Halama ED, Tilli MT et al (2005) Deregulated estrogen receptor alpha expression in mammary epithelial cells of transgeneic mice results in the development of ductal carcinoma in situ. Cancer Res 65:681–685PubMedGoogle Scholar
  13. 13.
    Wood CE, Hester JM, Appt SE, Geisinger KR, Cline JM (2008) Estrogen effects on epithelial proliferation and benign proliferative lesions in the postmenopausal primate mammary gland. Lab Invest 88(9):938–948PubMedGoogle Scholar
  14. 14.
    Simpson PT, Gale T, Reis-Filho JS et al (2005) Columnar cell lesions of the breast: the missing link in breast cancer progression? A morphological and molecular analysis. Am J Surg Pathol 29:734–746PubMedGoogle Scholar
  15. 15.
    Feeley L, Quinn CM (2008) Columnar cell lesions of the breast. Histopathology 52:11–19PubMedGoogle Scholar
  16. 16.
    Anderson E, Clarke RB (2004) Steroid receptors and cell cycle in normal mammary epithelium. J Mammary Gland Biol Neoplasia 9:3–13PubMedGoogle Scholar
  17. 17.
    Gompel A, Somai S, Chaouat M et al (2000) Hormonal regulation of apoptosis in breast cells and tissues. Steroids 65:593–598PubMedGoogle Scholar
  18. 18.
    Lee S, Medina D, Tsimelzon A et al (2007) Alterations of gene expression in the development of early hyperplastic precursors of breast cancer. Am J Pathol 171:252–262PubMedGoogle Scholar
  19. 19.
    Luetteke NC, Qiu TH, Fenton SE et al (1999) Targeted inactivation of the EGF and amphiregulin genes reveals distinct roles for EGF receptor ligands in mouse mammary gland development. Development 126:2739–2750PubMedGoogle Scholar
  20. 20.
    Troyer KL, Lee DC (2001) Regulation of mouse mammary gland development and tumorigenesis by the ERBB signaling network. J Mammary Gland Biol Neoplasia 6:7–21PubMedGoogle Scholar
  21. 21.
    Longacre TA, Bartow SA (1986) A correlative morphologic study of human breast and endometrium in the menstrual cycle. Am J Surg Pathol 10:382–393PubMedGoogle Scholar
  22. 22.
    Arpino G, Allred DC, Mohsin SK et al (2004) Lobular neoplasia on core-needle biopsy – clinical significance. Cancer 101:242–250PubMedGoogle Scholar
  23. 23.
    Schmitt FC (1995) Multistep progression from an oestorgen-dependent growth towards an autonomous growth in breast cancinogenesis. Eur J Cancer 31A:2049–2052PubMedGoogle Scholar
  24. 24.
    Barnes R, Masood S (1990) Potential value of hormone receptor assay in carcinoma in situ of breast. Am J Clin Pathol 94:533–537PubMedGoogle Scholar
  25. 25.
    De Potter CR, Praet MM, Slavin RE et al (1987) Feulgen DNA content and mitotic activity in proliferative breast disease: a comparison with ductal carcinoma in situ. Histopathology 7:1307–1319Google Scholar
  26. 26.
    Hoshi K, Tokunaga M, Mochizuki M et al (1995) Pathological characterization of atypical ductal hyperplasia of the breast. Jpn J Cancer Chemother 22(Supp 1):36–41Google Scholar
  27. 27.
    Clarke RB, Howell A, Potten CS et al (1997) Dissociation between steroid receptor expression and cell proliferation in the human breast. Cancer Res 57:4987–4991PubMedGoogle Scholar
  28. 28.
    Shocker BS, Jarvis C, Clarke RB et al (1999) Estrogen receptor-positive proliferating cells in the normal and precancerous breast. Am J Pathol 155:1811–1815Google Scholar
  29. 29.
    Bai M, Agnantis NJ, Sevasti K et al (2001) In vivo cell kinetics in breast carcinogenesis. Breast Cancer Res 3:276–283PubMedGoogle Scholar
  30. 30.
    Prosser J, Hilsenbeck SG, Fuqua SAW, et al. Cell turnover (proliferation and apoptosis) in normal epithelium and premalignant lesions in the same breast. Lab Invest 1997;76:119 [abstract 124A]Google Scholar
  31. 31.
    O’Connell P, Pekkel V, Fuqua SAW et al (1998) Analysis of loss of heterozygosity in 399 premalignant breast lesions at 15 genetic loci. J Natl Cancer Inst 90:697–703PubMedGoogle Scholar
  32. 32.
    Larson PS, de las Morenas A, Cerda SR et al (2006) Quantitative analysis of allele imbalance supports atypical ductal hyperplasia lesions as direct breast cancer precursors. J Pathol 209:307–316PubMedGoogle Scholar
  33. 33.
    Amari M, Suzuki A, Moriya T et al (1999) LOH analyses of premalignant and malignant lesions of human breast: frequent LOH in 8p, 16q, and 17q in atypical ductal hyperplasia. Oncol Rep 6:1277–1280PubMedGoogle Scholar
  34. 34.
    Chauqui RF, Zhuang Z, Emmert-Buck MR et al (1997) Analysis of loss of heterozygosity on chromosome 11q13 in atypical ductal hyperplasia and in situ carcinoma of the breast. Am J Pathol 150:297–303Google Scholar
  35. 35.
    Lakhani SR, Collins N, Stratton MR et al (1995) Atypical ductal hyperplasia of the breast: clonal proliferation with loss of heterozygosity on chromosomes 16q and 17p. J Clin Pathol 48:611–615PubMedGoogle Scholar
  36. 36.
    Rosenberg CL, de las Morenas A, Huang K et al (1996) Detection of monoclonal microsatellite alterations in atypical breast hyperplasia. J Clin Invest 98:1095–1100PubMedGoogle Scholar
  37. 37.
    Rosenberg CL, Larson PS, Romo JD et al (1997) Microsatellite alterations indicating monoclonality in atypical hyperplasias associated with breast cancer. Hum Pathol 28:214–219PubMedGoogle Scholar
  38. 38.
    Tsuda H, Takarabe T, Akashi-Tanaka S et al (2001) Pattern of chromosome 16q loss differs between an atypical proliferative lesion and an intraductal or invasive ductal carcinoma occurring subsequently in the same area of the breast. Mod Pathol 14:382–388PubMedGoogle Scholar
  39. 39.
    Ernster VL, Barclay J (1997) Increases in ductal carcinoma in situ (DCIS) of the breast in relation to mammography: a dilemma. Natl Cancer Inst Monogr 22:151–156Google Scholar
  40. 40.
    Ries LAG, Eisner MP, Kosary CL (2003) SEER cancer statistics review 1975–2000. National Cancer Institute, BethesdaGoogle Scholar
  41. 41.
    Society AC (2005) Breast cancer facts and figures 2005–2006. American Cancer Society, Inc., AtlantaGoogle Scholar
  42. 42.
    van de Vijver MJ, Peterse JL, Mooi WJ et al (1988) Neu-protein overexpression in breast cancer. Association with comedo-type ductal carcinoma in situ and limited prognostic value in stage II breast cancer. N Engl J Med 319:1239–1245PubMedGoogle Scholar
  43. 43.
    Allred DC, Clark GM, Molina R et al (1992) Overexpression of HER-2/neu and its relationship with other prognostic factors change during the progression of in situ to invasive breast cancer. Hum Pathol 23:974–979PubMedGoogle Scholar
  44. 44.
    Ottensen GL, Christensen IJ, Larsen JK et al (2000) Carcinoma in situ of the breast: correlation of histopathology to immunohistochemical markers and DNA ploidy. Breast Cancer Res Treat 60:219–226Google Scholar
  45. 45.
    Allred DC, Wu Y, Mao S et al (2008) Ductal carcinoma in situ and the emergence of diversity during breast cancer evolution. Clin Cancer Res 14:370–378PubMedGoogle Scholar
  46. 46.
    Leong AS, Sormunen RT, Vinyuvat S et al (2001) Biologic markers in ductal carcinoma in situ and concurrent infiltrating carcinoma. A comparison of eight contemporary grading systems. Am J Clin Pathol 115:709–718PubMedGoogle Scholar
  47. 47.
    Mack L, Kerkvliet N, Doig G et al (1997) Relationship of a new histological categorization of ductal carcinoma in situ of the breast with size and the immunohistochemical expression of p53, c-erb B2, bcl-2, and ki-67. Hum Pathol 28:974–979PubMedGoogle Scholar
  48. 48.
    Moreno A, Lloveras B, Figueras A et al (1997) Ductal carcinoma in situ of the breast: correlation between histologic classifications and biologic markers. Mod Pathol 10:1088–1092PubMedGoogle Scholar
  49. 49.
    Silverstein MJ, Cohlan BF, Gierson ED et al (1992) Duct carcinoma in situ: 227 cases without microinvasion. Eur J Cancer 28:630–634PubMedGoogle Scholar
  50. 50.
    Albonico G, Querzoli P, Feretti S et al (1996) Biophenotypes of breast carcinoma in situ defined by image analysis of biological parameters. Pathol Res Pract 192:117–123PubMedGoogle Scholar
  51. 51.
    Bose S, Lesser ML, Norton L et al (1996) Immunophenotype of intraductal carcinoma. Arch Pathol Lab Med 120:81–85PubMedGoogle Scholar
  52. 52.
    Chaudhuri B, Crist KA, Mucci S et al (1993) Distribution of estrogen receptor in ductal carcinoma in situ of the breast. Surgery 113:134–137PubMedGoogle Scholar
  53. 53.
    Giri DD, Dunda SAC, Nottingham JF et al (1989) Oestrogen receptors in benign epithelial lesions and intraduct carcinomas of the breast: an immunohistological study. Histopathology 15:575–584PubMedGoogle Scholar
  54. 54.
    Helin HJ, Helle MJ, Kallioneimi OP et al (1989) Immunohistochemical determination of estrogen and progesterone receptors in human breast carcinoma: correlation with histopathology and DNA flow cytometry. Cancer 63:1761–1767PubMedGoogle Scholar
  55. 55.
    Karayiannakis AJ, Bastounis EA, Chatzigianni EB et al (1996) Immunohistochemical detection of oestrogen receptors in ductal carcinoma in situ of the breast. Eur J Surg Oncol 22:578–582PubMedGoogle Scholar
  56. 56.
    Leal CB, Schmitt FC, Bento MJ et al (1995) Ductal carcinoma in situ of the breast. Histologic categorization and its relationship to ploidy and immunohistochemical expression of hormone receptors, p53, and c-erbB-2 protein. Cancer 75:2123–2131PubMedGoogle Scholar
  57. 57.
    Pallis L, Wilking N, Cedermark B et al (1992) Receptors for estrogen and progesterone in breast carcinoma in situ. Anticancer Res 12:2113–2115PubMedGoogle Scholar
  58. 58.
    Poller DN, Roberts EC, Bell JA et al (1993) p53 protein expression in mammary ductal carcinoma in situ: relationship to immunohistochemical expression of estrogen receptor and c-erbB-2 protein. Hum Pathol 24:463–468PubMedGoogle Scholar
  59. 59.
    Zafrani B, Leroyer A, Fourquet A et al (1994) Mammographically detected ductal in situ carcinoma of the breast analyzed with a new classification. A study of 127 cases: correlation with estrogen and progesterone receptors, p53, and c-erbB-2 proteins, and proliferative activity. Semin Diagn Pathol 11:208–214PubMedGoogle Scholar
  60. 60.
    Lodato RF, Maguire HC Jr, Greene MI et al (1990) Immunohistochemical evaluation of c-erbB-2 oncogene expression in ductal carcinoma in situ and atypical ductal hyperplasia of the breast. Mod Pathol 3:449–454PubMedGoogle Scholar
  61. 61.
    Barnes DM, Hanby AM, Gillett CE et al (1992) Abnormal expression of wild type p53 protein in normal cells of a cancer family patient. Lancet 340:259–263PubMedGoogle Scholar
  62. 62.
    Barnes DM, Meyer JS, Gonzalez JG et al (1991) Relationship between c-erbB-2 immunoreactivity and thymidine labeling index in breast carcinoma in situ. Breast Cancer Res Treat 18:11–17PubMedGoogle Scholar
  63. 63.
    Bartkova J, Barnes DM, Millis RR et al (1990) Immunohistochemical demonstration of c-erbB-2 protein in mammary ductal carcinoma in situ. Hum Pathol 21:1164–1167PubMedGoogle Scholar
  64. 64.
    Bobrow LG, Happerfield LC, Gregory WM et al (1994) The classification of ductal carcinoma in situ and its association with biological markers. Semin Diagn Pathol 11:199–207PubMedGoogle Scholar
  65. 65.
    De Potter CR, Foschini MP, Schelfhout AM et al (1993) Immunohistochemical study of neu protein overexpression in clinging in situ duct carcinoma of the breast. Virchows Arch A Pathol Anat 422:375–380Google Scholar
  66. 66.
    De Potter CR, Schelfhout A-M, Verbeeck P et al (1995) neu-Overexpression correlates with extent of disease in large cell ductal carcinoma in situ of the breast. Hum Pathol 26:601–606PubMedGoogle Scholar
  67. 67.
    Poller DN, Silverstein MJ, Galea M et al (1994) Ductal carcinoma in situ of the breast: a proposal for a new simplified histological classification association between cellular proliferation and c-erbB-2 protein expression. Mod Pathol 7:257–262PubMedGoogle Scholar
  68. 68.
    Ramachandra S, Machin L, Ashley S et al (1990) Immunohistochemical distribution of c-erbB-2 in in situ breast carcinoma: a detailed morphological analysis. J Pathol 161:7–14PubMedGoogle Scholar
  69. 69.
    Schimmelpenning H, Eriksson ET, Pallis L et al (1992) Immunohistochemical c-erbB-2 proto-oncogene expression and nuclear DNA content in human mammary carcinoma in situ. Am J Clin Pathol 97(Suppl):S48–S52PubMedGoogle Scholar
  70. 70.
    Somerville JE, Clarke LA, Biggart JD (1992) c-erbB-2 overexpression and histological type of in situ and invasive breast carcinomas. J Clin Pathol 45:16–20PubMedGoogle Scholar
  71. 71.
    Tsuda H, Iwaya K, Fukutomi T et al (1993) p53 mutations and c-erbB-2 amplification in intraductal and invasive breast carcinomas of high histologic grade. Jpn J Cancer Res 84:394–401PubMedGoogle Scholar
  72. 72.
    Chitemere M, Andersen TI, Hom R et al (1996) TP53 alterations atypical ductal hyperplasia and ductal carcinoma in situ of the breast. Breast Cancer Res Treat 41:103–109Google Scholar
  73. 73.
    Eriksson ET, Schmmelpenning H, Aspenblad U et al (1994) Immunohistochemical expression of the mutant p53 protein and nuclear DNA content during the transition from benign to malignant breast disease. Hum Pathol 25:1228–1233PubMedGoogle Scholar
  74. 74.
    O’Malley FP, Vnencak-Jones CL, Dupont WD et al (1994) p53 mutations are confined to the comedo type ductal carcinoma in situ of the breast: immunohistochemical and sequencing data. Lab Invest 71:67–72PubMedGoogle Scholar
  75. 75.
    Rajan PB, Scott DJ, Perry RH et al (1997) p53 protein expression in ductal carcinoma in situ (DCIS) of the breast. Breast Cancer Res Treat 42:283–290PubMedGoogle Scholar
  76. 76.
    Schmitt FC, Leal D, Lopes C (1995) p53 protein expression and nuclear DNA content in breast intraductal proliferations. J Pathol 176:233–241PubMedGoogle Scholar
  77. 77.
    Siziopikou KP, Prioleau JE, Harris JR et al (1996) Bcl-2 expression in the spectrum of preinvasive breast lesions. Cancer 77:499–506PubMedGoogle Scholar
  78. 78.
    Siziopikou KP, Schnitt SJ (2000) MIB-1 proliferation index in ductal carcinoma in situ of the breast: relationship to the expression of the apoptosis-regulating proteins bcl-2 and p53. Breast J 6:400–406PubMedGoogle Scholar
  79. 79.
    Walker RA, Dearing SJ, Lane DP et al (1991) Expression of p53 protein in infiltrating and in-situ breast carcinomas. J Pathol 165:203–211PubMedGoogle Scholar
  80. 80.
    Locker AP, Horrocks C, Gilmour AS et al (1990) Flow cytometric and histological analysis of ductal carcinoma in situ of the breast. Br J Surg 77:564–567PubMedGoogle Scholar
  81. 81.
    Meyer JS (1986) Cell kinetics of histologic variants of in situ breast carcinoma. Breast Cancer Res Treat 7:171–180PubMedGoogle Scholar
  82. 82.
    Bodis S, Siziopikou KP, Schitt SJ et al (1996) Extensive apoptosis in ductal carcinoma in situ of the breast. Cancer 77:1831–1835PubMedGoogle Scholar
  83. 83.
    Harn HJ, Shen KL, Yueh KC et al (1997) Apoptosis occurs more frequenty in intraductal carcinoma than in infiltrating duct carcinoma of human breast cancer and correlates with altered p53 expression: detected by terminal-deoxynucleotidyl-transferase-mediated dUTP-FITC nick end labelling (TUNEL). Histopathology 31:534–539PubMedGoogle Scholar
  84. 84.
    Gupta SK, Douglas-Jones AG, Morgan JM et al (1997) The clinical behavior of breast carcinoma is probably determined at the preinvasive stage (ductal carcinoma in situ). Cancer 80:1740–1745PubMedGoogle Scholar
  85. 85.
    Solin LJ, Kurtz J, Forquet A et al (1996) Fifteen-year results of breast-conserving surgery and definitive breast irradiation for the treatment of ductal carcinoma in situ of the breast. J Clin Oncol 14:754–763PubMedGoogle Scholar
  86. 86.
    Ma XJ, Salunga R, Tuggle JT et al (2003) Gene expression profiles of human breast cancer progression. Proc Natl Acad Sci U S A 100:5974–5979PubMedGoogle Scholar
  87. 87.
    Hannemann J, Velds A, Halfwerk JB et al (2006) Classification of ductal carcinoma in situ by gene expression profiling. Breast Cancer Res 8:R61PubMedGoogle Scholar
  88. 88.
    Porter D, Lahti-Domenici J, Keshaviah A et al (2003) Molecular markers in ductal carcinoma in situ of the breast. Mol Cancer Res 1:362–375PubMedGoogle Scholar
  89. 89.
    Polyak K (2008) Is breast tumor progression really linear? Clin Cancer Res 14:339–341PubMedGoogle Scholar
  90. 90.
    Polyak K (2007) Breast cancer: origins and evolution. J Clin Invest 117:3155–3163PubMedGoogle Scholar
  91. 91.
    Campbell LL, Polyak K (2007) Breast tumor heterogeneity: cancer stem cells or clonal evolution? Cell Cycle 6:2332–2338PubMedGoogle Scholar
  92. 92.
    Waldman FM, DeVries S, Chew KL et al (2000) Chromosomal alterations in ductal carcinomas in situ and their in situ recurrences. J Natl Cancer Inst 92:313–320PubMedGoogle Scholar
  93. 93.
    Hwang ES, DeVries S, Chew KL et al (2004) Patterns of chromosomal alterations in breast ductal carcinoma in situ. Clin Cancer Res 10:5160–5167PubMedGoogle Scholar
  94. 94.
    Smeds J, Warnberg F, Norberg T et al (2005) Ductal carcinoma in situ of the breast with different histopathological grades and corresponding new breast tumour events: analysis of loss of heterozygosity. Acta Oncol 44:41–49PubMedGoogle Scholar
  95. 95.
    Boecker W, Buerger H, Schmitz K et al (2001) Ductal epithelial proliferations of the breast: a biological continuum? Comparative genomic hybridization adn high-molecular-weight cytokeratin expression patterns. J Pathol 195:415–421PubMedGoogle Scholar
  96. 96.
    Aldaz CM, Chen T, Sahin A et al (1995) Comparative allelotype of in situ and invasive human breast cancer: high frequency of microsatellite instability in lobular breast carcinomas. Cancer Res 55:3976–3981PubMedGoogle Scholar
  97. 97.
    Chappell SA, Walsh T, Walker RA et al (1997) Loss of heterozygosity at chromosome 6q in preinvasive and early invasive breast carcinomas. Br J Cancer 75:1324–1329PubMedGoogle Scholar
  98. 98.
    Fujii H, Marsh C, Cairns P et al (1996) Genetic divergence in the clonal evolution of breast cancer. Cancer Res 56:1493–1497PubMedGoogle Scholar
  99. 99.
    Fujii H, Szumel R, Marsh C et al (1996) Genetic progression, histologic grade, and allelic loss in ductal carcinoma in situ of the breast. Cancer Res 56:5260–5265PubMedGoogle Scholar
  100. 100.
    Man S, Ellis IO, Sibbering M et al (1996) High levels of allele loss at the FHIT and ATM genes in non-comedo ductal carcinoma in situ and grade I tubular invasive breast cancers. Cancer Res 56:5484–5489PubMedGoogle Scholar
  101. 101.
    Munn KE, Walker RA, Varley JM (1995) Frequent alterations of chromosome 1 in ductal carcinoma in situ of the breast. Oncogene 10:1653–1657PubMedGoogle Scholar
  102. 102.
    Radford DM, Fair KL, Phillips NJ et al (1995) Allelotyping of ductal carcinoma in situ of the breast: deletion of loci on 8p, 13q, 16q, 17p and 17q. Cancer Res 55:3399–3405PubMedGoogle Scholar
  103. 103.
    Stratton MR, Collins N, Lakhani SR et al (1995) Loss of heterozygosity in ductal carccinoma in situ of the breast. J Pathol 175:195–201PubMedGoogle Scholar
  104. 104.
    Bissell MJ, Radisky D (2001) Putting tumours in context. Nat Rev Cancer 1:46–54PubMedGoogle Scholar
  105. 105.
    Tuxhorn JA, Ayala GE, Rowley DR (2001) Reactive stroma in prostate cancer progression. J Urol 166:2472–2483PubMedGoogle Scholar
  106. 106.
    Park CC, Bissell MJ, Barcellos-Hoff MH (2000) The influence of the microenvironment on the malignant phenotype. Mol Med Today 6:324–329PubMedGoogle Scholar
  107. 107.
    Barcellos-Hoff MH, Ravani SA (2000) Irradiated mammary gland stroma promotes the expression of tumorigenic potential by unirradiated epithelial cells. Cancer Res 60:1254–1260PubMedGoogle Scholar
  108. 108.
    Frazier KS, Grotendorst GR (1997) Expression of connective tissue growth factor mRNA in the fibrous stroma of mammary tumors. Int J Biochem Cell Biol 29:153–161PubMedGoogle Scholar
  109. 109.
    Kalluri R, Zeisberg M (2006) Fibroblasts in cancer. Nat Rev Cancer 6:392–401PubMedGoogle Scholar
  110. 110.
    Olumi AF, Grossfeld GD, Hayward SW et al (1999) Carcinoma-associated fibro blasts direct tumor progression of initiated human prostatic epithelium. Cancer Res 59:5002–5011PubMedGoogle Scholar
  111. 111.
    Allinen M, Beroukhim R, Cai L et al (2004) Molecular characterization of the tumor microenvironment in breast cancer. Cancer Cell 6:17–32PubMedGoogle Scholar
  112. 112.
    Hu M, Yao J, Cai L et al (2005) Distinct epigenetic changes in the stromal cells of breast cancers. Nat Genet 37:899–905PubMedGoogle Scholar
  113. 113.
    Qiu W, Hu M, Sridhar A et al (2008) No evidence of clonal somatic genetic alterations in cancer-associated fibroblasts from human breast and ovarian carcinomas. Nat Genet 40:650–655PubMedGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2011

Authors and Affiliations

  1. 1.Department of Pathology and ImmunologyWashington University School of MedicineSt. LouisUSA

Personalised recommendations